{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-137922","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.749208+00:00","generated_at":"2026-05-29T01:59:03.072168+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Akari Therapeutics appoints Samir R. Patel as permanent CEO, adds Abizer Gaslightwala to board","bullets":["Dr. Samir R. Patel appointed CEO effective Dec 16, 2024; he served as interim CEO since May 2024.","Abizer Gaslightwala appointed as Class A director effective Dec 16, 2024; term expires at 2025 AGM.","Michael Grissinger resigned from board on Dec 16, 2024; no disagreement with company operations.","Gaslightwala is SVP at Jazz Pharma, previously at Amgen and Pfizer; deemed independent under Nasdaq rules."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-137922","json":"https://secwatch.observer/filing/0000950170-24-137922.json","markdown":"https://secwatch.observer/filing/0000950170-24-137922.md","text":"https://secwatch.observer/filing/0000950170-24-137922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024137922/0000950170-24-137922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024137922/aktx-20241212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:59:03.072168+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}